Comparison of tumor response and outcomes of patients with hepatocellular carcinoma after multimodal treatment including immune checkpoint inhibitors – a systematic review and meta-analysis
HPB · 2024-05 · 26 (5) · 618-629
DOI: 10.1016/j.hpb.2024.02.003 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift HPB, 2024-05. Verfasst von Zaiba S Dawood und 10 weiteren Autor:innen. Beteiligte Einrichtung: Medical College, The Aga Khan University Hospital, Stadium Road, Karachi, 74800, Pakistan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Immune Checkpoint Inhibitors, Chemoembolization, Therapeutic. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 78 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: The efficacy of immune checkpoint inhibitors (ICIs) combined with tyrosine kinase inhibitors (TKIs), trans-arterial chemoembolization (TACE), and radiotherapy to treat hepatocellular carcinoma (HCC) has not been well-defined. We performed a meta-analysis to characterize tumor response and survival associated with multimodal treatment of HCC. METHODS: PubMed, Embase, Medline, Scopus, and CINAHL databases were searched (1990-2022). Random-effect meta-analysis was conducted to compare efficacy of treatment modalities. Odds ratios (OR) and standardized mean difference (SMD) were reported. RESULTS: Thirty studies (4170 patients) met inclusion criteria. Triple therapy regimen (ICI + TKI + TACE) had the highest overall disease control rate (DCR) (87%, 95% CI 83-91), while ICI + radiotherapy had the highest objective response rate (ORR) (72%, 95% CI 54%-89%). Triple therapy had a higher DCR than ICI + TACE (OR 4.49, 95% CI 2.09-9.63), ICI + TKI (OR 3.08, 95% CI 1.63-5.82), and TKI + TACE (OR 2.90, 95% CI 1.61-5.20). Triple therapy demonstrated improved overall survival versus ICI + TKI (SMD 0.72, 95% CI 0.37-1.07) and TKI + TACE (SMD 1.13, 95% CI 0.70-1.48) (both p 0.05). CONCLUSION: The combination of ICIs, TKIs and TACE demonstrated superior tumor response and survival and should be considered for select patients with advanced HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Medical College, The Aga Khan University Hospital, Stadium Road, Karachi, 74800, Pakistan.
- Department of Surgery, New York University Long Island School of Medicine, Mineola, NY, USA.
- Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH, USA.
- Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH, USA. Electronic address: Tim.Pawlik@osumc.edu.
Zitieren
APA
Dawood, Z. S., Brown, Z. J., Alaimo, L., Lima, H. A., Shaikh, C., Katayama, E. S., Munir, M. M., Moazzam, Z., Endo, Y., Woldesenbet, S., & Pawlik, T. M. (2024). Comparison of tumor response and outcomes of patients with hepatocellular carcinoma after multimodal treatment including immune checkpoint inhibitors – a systematic review and meta-analysis. HPB, 26(5), 618-629. https://doi.org/10.1016/j.hpb.2024.02.003
Vancouver
Dawood ZS, Brown ZJ, Alaimo L, Lima HA, Shaikh C, Katayama ES, et al. Comparison of tumor response and outcomes of patients with hepatocellular carcinoma after multimodal treatment including immune checkpoint inhibitors – a systematic review and meta-analysis. HPB. 2024;26(5):618-629. doi:10.1016/j.hpb.2024.02.003
BibTeX
@article{Dawood2024,
author = {Dawood, Zaiba S and Brown, Zachary J and Alaimo, Laura and Lima, Henrique A and Shaikh, Chanza and Katayama, Erryk S and Munir, Muhammad M and Moazzam, Zorays and Endo, Yutaka and Woldesenbet, Selamawit and Pawlik, Timothy M},
title = {Comparison of tumor response and outcomes of patients with hepatocellular carcinoma after multimodal treatment including immune checkpoint inhibitors – a systematic review and meta-analysis},
journal = {HPB},
year = {2024},
volume = {26},
number = {5},
pages = {618--629},
doi = {10.1016/j.hpb.2024.02.003}
}
EUVIMED